19:20 Aug 8, 2020 |
English to Spanish translations [PRO] Medical - Medical (general) / General | |||||||
---|---|---|---|---|---|---|---|
|
| ||||||
| Selected response from: Brent Sørensen Germany Local time: 06:36 | ||||||
Grading comment
|
Summary of answers provided | ||||
---|---|---|---|---|
3 +4 | datos de eficacia |
| ||
5 | información sobre la eficacia |
| ||
3 | Datos sobre el uso de todos los recursos para tratamientos |
|
Discussion entries: 3 | |
---|---|
datos de eficacia Explanation: https://www.sciencedirect.com/science/article/pii/S1699258X1... Certolizumab pegol Yes, it’s a fairly literal translation. But I don’t think there are many other way you can say it. And especially when it comes to scientific writing, a simple and direct style of writing is best. Abstract Certolizumab pegol is a new anti-TNF drug formed by the Fab’ fragment of a humanized mouse monoclonal antibody bound to two molecules of polyethylene glycol. Certolizumab pegol recognizes and binds to human TNF-α, both in its soluble and membrane bound form, and has shown clinical efficacy in controlled trials for the treatment of RA and Crohns’ disease. In this review we summarize the structural characteristics and clinical efficacy data, as well as safety data of this anti-TNF agent in patients with RA. Resumen El certolizumab pegol es un nuevo fármaco anti-TNF formado por el fragmento Fab’ de un anticuerpo monoclonal murino humanizado unido a dos moléculas de polietilenglicol. El certolizumab pegol reconoce y neutraliza el TNF-α humano, soluble y unido a membrana, y ha demostrado eficacia clínica en ensayos controlados en la AR y en la enfermedad de Crohn. En esta revisión se resumen las características estructurales y los datos de eficacia clínica, de prevención del daño estructural, así como los datos de seguridad de este anti-TNF en pacientes con AR. |
| |
Grading comment
| ||